Abeona Therapeutics Announces FDA Clearance of Investigational New Drug Application for ABO-202 Gene Therapy in CLN1 Disease
NEW YORK and CLEVELAND, May 21, 2019 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced that the Company is cleared to begin a Phase 1/2 clinical trial evaluating its novel, one-time gene therapy ABO-202 for the treatment of CLN1 disease, following acceptance of its Investigational New Drug (IND) application by the U.S. Food and Drug Administration (FDA). ABO-202 is designed to deliver a functional copy of the PPT1 gene to cells of the central nervous system and peripheral organs using a combined intravenous and intrathecal delivery via the AAV9 vector. The Company will provide guidance on the timing of the clinical trial later this year.
“This significant step brings hope to people impacted by this devastating disease and was achieved in partnership with Dr. Steven Gray and Taylor’s Tale,” said Timothy J. Miller, Ph.D., Co-Founder, President & Chief Scientific Officer. “We are very encouraged that ABO-202 was well-tolerated and demonstrated significant efficacy in preclinical studies. These results are consistent with findings in our other pre-clinical studies for AAV9-based programs for lysosomal storages diseases, MPS IIIA and MPS IIIB.”
In preclinical studies, ABO-202 effectively delivered a functional copy of the PPT1 gene to the central nervous system and peripheral organs. IND-enabling studies in a CLN1 animal model demonstrated that ABO-202 normalized survival and led to improvement of neurological function in affected mice. These studies also showed that combination intravenous and intrathecal dosing provided incremental efficacy over either delivery route alone and thus may enhance the therapeutic potential of this gene therapy.
ABO-202 is a one-time AAV gene therapy designed to enable cells to produce the normal PPT1 enzyme, which is critical for proper lysosomal function. Lack of this enzyme in patients with CLN1 disease results in neuroinflammation and neurodegeneration. ABO-202 has been granted Orphan Drug and Rare Pediatric Disease designations by the FDA and has received Orphan Medicinal Product designation in the EU. The global trial will be conducted at centers of excellence in CLN1 research, including the University of Rochester Medical Center in the U.S. and the University of Hamburg-Eppendorf in Germany.
“ABO-202 is a promising AAV9 gene therapy that extended survival and improved neurological function in the animal model of CLN1 disease. Importantly, the combined intravenous and intrathecal administration approach showed additional benefits compared to a single route of delivery, providing a new treatment paradigm for patients with devastating neurological diseases,” said Steven J. Gray, Ph.D., Batten disease researcher and Associate Professor, Pediatrics, UT Southwestern Medical Center.
About CLN1 disease (Infantile Batten disease)
CLN1 disease, also known as Infantile Neuronal Ceroid Lipofuscinosis or infantile Batten disease, is a rapidly-progressing rare lysosomal storage disease with no approved treatment. It primarily affects the central nervous system and typically manifests during the first year of life with vision impairment that can progress to blindness, progressive motor and cognitive decline, seizures and ultimately early death. The underlying cause of the disorder is a defect in the PPT1 gene that encodes the enzyme of the same name, resulting in the accumulation of lipopigments within cells, leading to neuroinflammation and neurodegeneration. Some patients with CLN1 disease develop symptoms later in childhood or in adulthood; these variants are called late-infantile, juvenile, or adult-onset CLN1.
ABO-202 is a novel, one-time gene therapy for CLN1 disease, a rapidly-progressing rare lysosomal storage disease with no approved therapy. ABO-202 is dosed through intravenous and intrathecal infusions using the AAV9 vector to deliver a functional copy of the PPT1 gene to cells of the central nervous system and peripheral organs. Preclinical data demonstrated that combination intravenous and intrathecal dosing may enhance the therapeutic potential of ABO-202. The therapy is designed to address the underlying gene and enzyme deficiency that leads to abnormal buildup of lipopigments and results in neuroinflammation and neurodegeneration.
About Abeona Therapeutics
Abeona Therapeutics Inc. is a clinical-stage biopharmaceutical company developing gene and cell therapies for serious diseases. The Company’s clinical programs include EB-101, its autologous, gene-corrected cell therapy for recessive dystrophic epidermolysis bullosa, as well as ABO-102 and ABO-101, novel AAV9-based gene therapies for Sanfilippo syndrome types A and B (MPS IIIA and MPS IIIB), respectively. The Company’s portfolio of AAV9-based gene therapies also features ABO-202 and ABO-201 for CLN1 disease and CLN3 disease, respectively. Its preclinical assets include ABO-401, which uses the novel AIM™ AAV vector platform to address all mutations of cystic fibrosis. Abeona has received numerous regulatory designations from the FDA and EMA for its pipeline candidates and is the only company with Regenerative Medicine Advanced Therapy designation for two candidates (EB-101 and ABO-102). For more information, visit www.abeonatherapeutics.com.
Forward Looking Statement
This press release contains certain statements that are forward-looking within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and that involve risks and uncertainties. These statements include statements regarding our pipeline including the therapeutic potential for ABO-202 in the treatment of CLN1, including the ability to effectively treat CLN1 disease in human patients, the ability to obtain regulatory marketing approvals, and the company’s goals and objectives. We have attempted to identify forward looking statements by such terminology as “may,” will,” “anticipate,” “believe,” “estimate,” “expect,” “intend,” and similar expressions.
Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, numerous risks and uncertainties, including but not limited to: continued interest in our rare disease portfolio, our ability to initiate and enroll patients in clinical trials, the impact of competition, the ability to secure licenses for any technology that may be necessary to commercialize our products, the ability to achieve or obtain necessary regulatory approvals, the impact of changes in the financial markets and global economic conditions, risks associated with data analysis and reporting, and other risks as may be detailed from time to time in the Company’s annual reports on Form 10-K and quarterly reports on Form 10-Q and other reports filed by the Company with the Securities and Exchange Commission. The Company undertakes no obligation to revise the forward-looking statements or update them to reflect events or circumstances occurring after the date of this presentation, whether as a result of new information, future developments or otherwise, except as required by the federal securities laws.
Senior Director, Investor Relations
+1 (646) 813-4710
Director, Corporate Communications
+1 (718) 344-5843
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Følg saker fra GlobeNewswire
Registrer deg med din epostadresse under for å få de nyeste sakene fra GlobeNewswire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra GlobeNewswire
Sanan IC Expands Wafer Foundry Portfolio for Power Electronics with 150mm GaN-on-Silicon Process24.6.2019 15:00:00 CEST | Pressemelding
SUNNYVALE, Calif., June 24, 2019 (GLOBE NEWSWIRE) -- SANAN INTEGRATED CIRCUIT CO., LTD. (Sanan IC), a pure-play wafer foundry with its advanced compound semiconductor technology platform, today announced the commercial release of its 150mm gallium nitride (GaN) on silicon wafer foundry services intended for the latest high voltage AC/DC and DC/AC power electronics applications in the global market. Sanan IC’s new G06P111 is a 650V enhanced-mode high-electron-mobility transistor (E-HEMT) GaN process which adds to the company’s power electronics wafer foundry portfolio of wide bandgap (WBG) compound semiconductors that includes 100mm and 150mm silicon carbide (SiC) for high voltage Schottky Barrier Diodes (SBD). Leveraging years of high volume GaN manufacturing experience by Sanan Optoelectronics Inc., its parent company, for the LED market, Sanan IC is able to complement its foundry services with in-house MOCVD growth capabilities of high voltage, low leakage GaN-on-silicon epitaxial wa
Nasdaq Promotes Tal Cohen to Executive Vice President, North American Market Services24.6.2019 14:30:00 CEST | Pressemelding
Tom Wittman to become Executive Advisor and to retire from Nasdaq at year-end NEW YORK, June 24, 2019 (GLOBE NEWSWIRE) -- Nasdaq, Inc. today announced it has named Tal Cohen as Executive Vice President, North American Market Services, effective July 1. In this role, Cohen will be responsible for driving the strategy and success of our trading businesses across cash equities, commodities, derivatives, and trade management services in Nasdaq’s U.S. and Canadian markets. In his role, in addition to directing the strategy of the business, Cohen will oversee Nasdaq’s North American trading products across their lifecycle and will manage client relationships and market operations. He will report to Adena Friedman, President and CEO, Nasdaq. Cohen joined Nasdaq in April 2016 as Senior Vice President of North American Equities following the acquisition of Chi-X Canada, where he had served as CEO of Chi-X Global Holdings for six years. Prior to Chi-X, Cohen held senior positions at Instinet, Am
U.S. Army awards Vricon contract for One World Terrain24.6.2019 14:30:00 CEST | Pressemelding
Vricon to apply its Globe in 3D solution to support military training anywhere in the world McLean, VA, June 24, 2019 (GLOBE NEWSWIRE) -- Vricon is pleased to announce that on 14 June 2019, the U.S. Army, working through the Training and Readiness Accelerator, awarded Vricon an Other Transaction Agreement to build One World Terrain (OWT). One of the key objectives of OWT is to provide an accurate and realistic 3D global terrain that replicates the military’s operational environment. Specifically, OWT is part of the Synthetic Training Environment's Common Synthetic Environment (CSE). The CSE is the platform enabler of the Synthetic Training Environment that will allow units and soldiers to conduct realistic, multi-echelon collective training anywhere in the world. The Common Synthetic Environment is composed of three foundational capabilities: One World Terrain, Training Management Tool, and Training Simulation Software. “We are honored that the Army chose the Vricon solution for its On
WorkForce Software Announces Strategic Growth Investment from Evergreen Coast Capital24.6.2019 14:00:00 CEST | Pressemelding
Investment to Accelerate WorkForce Software’s Global Expansion and Commitment to Customer-First Innovation LIVONIA, Mich., June 24, 2019 (GLOBE NEWSWIRE) -- WorkForce Software®, a leading global provider of cloud-based workforce management solutions, announced today a significant equity investment from affiliates of Evergreen Coast Capital Corp. (“Evergreen”), the technology-focused private equity arm of Elliott Management Corporation. With the investment, Evergreen will become equal partners with Insight Partners, which has been the majority investor in WorkForce Software since 2014. Terms of the transaction were not disclosed. Founded in 1999, WorkForce Software is making work easy for the connected workforce around the globe. The company’s cloud-based solutions enable enterprise and mid-sized organizations to digitize time and attendance processes, optimize employee scheduling, simplify absence management, and gain strategic business insights. WorkForce Software was the first workfo
Minerva Neurosciences Announces Achievement of Primary and Key Secondary Objectives in Phase 2b Clinical Trial of Seltorexant (MIN-202) in Insomnia24.6.2019 13:30:00 CEST | Pressemelding
Primary endpoint, defined as Latency to Persistent Sleep (LPS) at Night 1, showed improvement with a p-value ≤0.001 after treatment with 10 and 20 mg doses of seltorexant Key secondary endpoint, defined as Wake After Sleep Onset over first 6 hours (WASO‑6) at Night 1, showed improvement with a p-value ≤0.005 after treatment with 10 and 20 mg doses of seltorexant Treatment with 10 and 20 mg doses of seltorexant showed greater improvement compared to zolpidem in LPS and WASO-6 Beneficial effects maintained over time Effects consistent in both adult and elderly patients Safety and tolerability profile comparable to placebo in both adults and elderly Potential first-in-class specific orexin-2 receptor antagonist for the treatment of insomnia Company to host conference call at 8:30 a.m. today (dial-in information below) WALTHAM, Mass., June 24, 2019 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the development of therap
Camunda Announces Extensive Speaker Lineup for CamundaCon 201924.6.2019 09:00:00 CEST | Pressemelding
Early Bird Tickets for the annual Camunda Community event available until June 30 BERLIN, June 24, 2019 (GLOBE NEWSWIRE) -- Camunda, an open source software company reinventing workflow automation, today announced the speaker lineup for its annual user conference – CamundaCon – featuring presenters from LinkedIn, Roche and AXA, among others. Demand for the tech-focused event is significantly outpacing last year and discounted Early Bird tickets are available only until June 30. CamundaCon, an event created for software developers, enterprise architects and IT executives who want to learn about workflow and decision automation, takes place September 12-13 in the heart of Berlin. It brings together workflow automation and BPMN experts, the global Camunda community and the Camunda engineering team to share best practices, discuss the product roadmap and get inspiration from fellow Camunda users. New this year to the annual conference is a developer-focussed track, with dedicated tutorials